| Home Market Dynamics Macro Trends Sector Trends Company Insights AI Investing Strategies Sign Up Login |
Sector: Pharmaceuticals
| Eli Lilly is making significant strides in product development, particularly with its successful launch of the GLP-1 weight loss pill, Foundayo, and the commitment to expand its capabilities in cancer treatment and genetic medicine. The acquisition of CrossBridge Bio further reinforces its focus on innovative drug technology, particularly in the biotech sector. However, challenges remain regarding the effectiveness of new Alzheimer's drugs, casting doubt on certain developments within the portfolio. Overall, the company's efforts to introduce new products and expand existing ones position it favorably in the pharmaceutical market. |
| The price action of Eli Lilly (LLY) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The trend sentiment at -0.2 is modestly bearish. The market sentiment at 1.5 is very bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next. There is no clear direction for LLY since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 1.5, and the negative at -0 on 2026-04-20. The forces of and Stock Price Trend (-0.2) will drive down the price. The forces of Price Level Sentiment (0), Sector Price Trend (0.2), Option Sentiment (0.8), Sentiment towards Fundamentals (2.2), Valuation Sentiment (2.9), and Market Risk Appetite (3) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
Sign up to reveice notifications on Market Movers
| LLY | ||||||||||||||
| Date | Attention | Price | StdDev | Price Level | Change | 10 Day Trend | Trend Sentiment | Hourly Trend Sentiment | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-20 | 1%(0.3%) | 921.27 | 2.28% | 51 | -0.6% | -0.05% | -0.2 | -0.1 | 0.9% | 1.5 | Short | 55% | 2.2 | 6.2 |
| 2026-04-19 | 1%(0.1%) | -0.4 | -0.1 | 1 | 1.4 | 5.5 | ||||||||
| 2026-04-18 | 0%(0%) | -0.4 | -0.1 | 1 | 1.4 | -1 | ||||||||
| 2026-04-17 | 0%(0%) | 926.79 | 2.29% | 58 | 2.59% | -0.1% | -0.4 | 0.5 | 1.1% | 1.1 | Long | 55% | 1.7 | 4 |
| 2026-04-16 | 0%(0%) | 903.43 | 2.34% | 31 | -0.19% | -0.55% | -1.8 | -0.4 | 1.2% | 0.6 | Short | 65% | 1.1 | 5.5 |
| 2026-04-15 | 0%(0%) | 905.13 | 2.3% | 32 | -1.94% | -0.16% | -1.3 | -0.5 | 1.5% | 0.7 | Short | 55% | 1.8 | -5.5 |
| 2026-04-14 | 0%(0%) | 923.03 | 2.24% | 52 | -0.67% | 0.39% | -0.2 | -0.4 | 0.5% | 0.9 | Short | 55% | 1.9 | -1 |
| 2026-04-13 | 0%(0%) | 929.23 | 2.72% | 54 | -1.09% | 0.56% | 0.4 | -0.3 | 1.1% | 0.8 | Short | 55% | 2.1 | -1 |
| 2026-04-12 | 0%(0%) | 0.4 | -0.3 | 0.7 | 1.5 | -1 | ||||||||
| 2026-04-11 | 0%(0%) | 0.4 | -0.3 | 0.8 | 1.9 | 6 | ||||||||
| Short is the preferred trading strategy with 55% chance of being right. Weak trend sentiment and negative hourly trend. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | ||||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | ||||||||||||||
| Analysis | ||
| ● Eli Lilly (LLY) – Equity Research Report Tue. Mar 17, 2026 | ||
| 2026-04-20 22:47:06 The emphasis on developing blood cancer therapies indicates a strong commitment to advancing medical treatments and addressing critical health issues. |
| 2026-04-20 22:47:06 Eli Lilly's acquisition of Kelonia demonstrates a strategic investment in biotech aimed at enhancing their portfolio in blood cancer therapies. |
| 2026-04-20 17:48:37 Eli Lilly's move to acquire Kelonia is indicative of a larger industry trend where major pharmaceutical companies are consolidating resources for competitive advantages in cancer therapy. |
| 2026-04-20 17:48:37 The articles discuss Eli Lilly's commitment to developing blood cancer therapies through its acquisition, reflecting a positive trend in expanding treatment options in the oncology field. |
| 2026-04-20 17:48:37 Eli Lilly's strategic acquisition of Kelonia Therapeutics highlights a significant investment in the biotechnology sector aimed at enhancing its portfolio in cancer therapeutics. |
| 2026-04-20 17:01:58 Ongoing legal and regulatory challenges associated with Eli Lilly's weight loss franchise highlight potential risks to its revenue streams. |
| 2026-04-20 17:01:58 Analyst upgrades of Eli Lilly's rating signify positive market sentiment regarding its future growth and performance potential. |
| 2026-04-20 17:01:58 Eli Lilly's expansion of its genetic medicine capabilities through the acquisition is poised to enhance its position in innovative treatment solutions. |
| 2026-04-20 17:01:58 Recent fluctuations in Eli Lilly's stock price reflect market reactions to its acquisition and overall business performance. |
| 2026-04-20 17:01:58 Eli Lilly's strategic move to acquire Kelonia Therapeutics highlights its commitment to enhancing its capabilities in cancer treatment and genetic medicine. |
| 2026-04-20 15:48:28 The potential acquisition is expected to positively influence Eli Lilly's stock performance due to its focus on developing blood cancer therapies. |
| 2026-04-20 15:48:28 Eli Lilly's significant financial investment in acquiring Kelonia showcases strategic growth through partnership in the healthcare industry. |
| 2026-04-20 11:48:50 The deal with Kelonia represents a broader trend toward innovative therapies in the cancer treatment landscape. |
| 2026-04-20 11:48:50 The combination of the GLP-1 pill approval and the acquisition is expected to influence Eli Lilly's stock valuation positively. |
| 2026-04-20 11:48:50 The approval of Eli Lilly's GLP-1 weight loss pill, Foundayo, signifies a significant advancement in their product offerings and potential market traction. |
| 2026-04-20 11:48:50 Eli Lilly's strategic acquisition of Kelonia Therapeutics for up to $7 billion highlights its focus on expanding its cancer treatment portfolio. |
| 2026-04-20 09:34:28 Eli Lilly's investment in Kelonia signifies a commitment to advancing healthcare innovations in blood cancer treatment. |
| 2026-04-20 09:34:28 The deal's implications for Eli Lilly's stock performance represent a positive outlook for investors and market analysts. |
| 2026-04-20 09:34:28 The article focuses on Eli Lilly's significant acquisition, which highlights a strategic move to bolster its cancer therapy portfolio. |